Trial Profile
The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Therapeutic Use
- 08 Feb 2019 Status changed from recruiting to completed.
- 15 Jun 2018 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
- 15 Jun 2018 Planned primary completion date changed from 1 May 2018 to 31 Dec 2018.